Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-13
2009-08-11
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S084000
Reexamination Certificate
active
07572805
ABSTRACT:
The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula Ior pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R3, R7, R8, R9, R10, R11and X are described herein.
REFERENCES:
patent: 2003/0187254 (2003-10-01), Perry et al.
patent: WO 99/09025 (1999-02-01), None
patent: WO 03/014121 (2003-02-01), None
patent: WO 2004/065351 (2004-08-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Hcaplus 1981:461933 , “The Schmidt reaction on 3a, 4, 5, 6-tetrahydrosuccinimido [3, 4-b] acenapthen-1o-one and its alkylated derivatives”, Campaigne et. al., 1981.
U.S. Appl. No. 11/180,861, filed Jul. 13, 2005, Fevig et al.
Chojnacka-Wójcik, E. et al., “Involvement of 5-HT2CReceptors in the m-CPP-Induced Antinociception in Mice”, Pol. J. Pharmacol., vol. 46, pp. 423-428 (1994).
Cryan, J.F. et al., “Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2CReceptors”, The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, pp. 1120-1126 (2000).
Di Matteo, V. et al., “Role of 5-HT2Creceptors in the control of central dopamine function”, Trends in Pharmacological Sciences, vol. 22, No. 5, pp. 229-232 (2001).
Grottick, A.J. et al., “Activation of 5-HT2Creceptors reduces the locomotor and rewarding effects of nicotine”, Psychopharmacology, vol. 157, pp. 292-298 (2001).
Grottick, A.J. et al., “Studies to Investigate the Role of 5-HT2CReceptors on Cocaine- and Food-Maintained Behavior”, The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, pp. 1183-1191 (2000).
Hoffman, B.J. et al., “Distribution of serotonin 5-HT1Creceptor mRNA in adult rat brain”, FEBS Letters, vol. 247, No. 2, pp. 453-462 (1989).
Hoyer, D. et al., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)”, Pharmacological Reviews, vol. 46, No. 2, pp. 157-203 (1994).
Jones, K. et al., “Intramolecular Reactions Using Amide Links: Aryl Radical Cyclisation of Silylated Acryloylanilides”, Tetrahedron Letters, vol. 35, No. 41, pp. 7673-7676 (1994).
Mazzola-Pomietto, P. et al., “Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2Creceptors”, Psychopharmacology, vol. 123, pp. 333-339 (1996).
Millan, M.J. et al., “5-HT2Creceptors mediate penile erections in rats: actions of novel and selective agonists and antagonists”, European Journal of Pharmacology, vol. 325, pp. 9-12 (1997).
Nonogaki, K. et al., “Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2Creceptor gene”, Nature Medicine, vol. 4, No. 10, pp. 1152-1156 (1998).
Nyerges, M. et al., “A Convenient Synthesis of Pyrrolo[3,4-c]quinolines”, Heterocyclic Communications, vol. 9, No. 3, pp. 239-242 (2003).
Rittenhouse, P.A. et al., “Evidence that ACTH Secretion Is Regulated by Serotonin2A/2C(5-HT2A/2C) Receptors”, The Journal of Pharmacology and Experimental Therapeutics, vol. 271, No. 3, pp. 1647-1655 (1994).
Sharpley, A.L. et al., “Slow Wave Sleep in Humans: Role of 5-HT2Aand 5-HT2CReceptors”, Neuropharmacology, vol. 33, No. 3/4, pp. 467-471 (1994).
Vickers, S.P. et al., “Comparative effects of continuous infusion ofmCPP, Ro 60-0175 andd-fenfluramine on food intake, water intake, body weight and locomotor activity in rats”, British Journal of Pharmacology, vol. 130, pp. 1305-1314 (2000).
Vickers, S.P. et al., “Evidence that hypophagia induced byd-fenfluramine andd-norfenfluramine in the rat is mediated by 5-HT2Creceptors”, Neuropharmacology, vol. 41, pp. 200-209 (2001).
Vickers, S.P. et al., “Reduced satiating effect ofd-fenfluramine in serotonin 5-HT2Creceptor mutant mice”, Psychopharmacology, vol. 143, pp. 309-314 (1999).
Virányi, A. et al., “A Convenient Synthesis of Pyrrolo[3,4-c]quinolines”, Synthesis, No. 17, pp. 2655-2660 (2003).
Caplus English Abstract DN 96:104021 Achini Roland, 1981, 64(7), pp. 2203-2218. See RN #80896-99, 80897-00, 80897-01.
Ahmad Saleem
Feng Jianxin
Fevig John M.
Andres Janet L
Bogie Terence J.
Bristol--Myers Squibb Company
Robinson Binta M
LandOfFree
Pyrrolo(oxo)isoquinolines as 5HT ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo(oxo)isoquinolines as 5HT ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo(oxo)isoquinolines as 5HT ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108642